Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFILE 1014: Crizotinib vs pemetrexed + platinum in ALK-positive non-squamous NSCLC
jRCT2080221424Phase 3
- Sponsor
- Pfizer
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of crizotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221424.